CLDN4 and lobular breast carcinoma in situ: For example, overexpression of claudin-4 suggested shorter 5-year progression-free survival and overall survival of ovarian cancer [34], while low expression of claudin-4 indicated a shorter disease-free survival of breast carcinoma in situ [35].